Business
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced its abstract has been accepted for poster presentation at the Acute Leukemias XIX (ISALXIX) International Symposium being held March 16-19, 2025 in Munich, Germany.
About this update from Moleculin Biotech, Inc.
[{"type":"text","content":"HOUSTON, March 3, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced its abstract has been accepted for poster presentation at the Acute Leukemias XIX (ISALXIX) International Symposium being held March 16-19, 2025 in Munich, Germany.","length":433,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Moleculin Biotech, Inc.) (PRNewsfoto/Moleculin Biotech, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Moleculin Biotech, Inc.) (PRNewsfoto/Moleculin Biotech, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":169,"url":"https://media.zenfs.com/en/prnewswire.com/a131ccb072f14b586ccff26f773457fd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4oyeskmHQzGI9EuYCvNaXA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI5ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a131ccb072f14b586ccff26f773457fd","width":400,"height":169}},"href":"https://mma.prnewswire.com/media/959635/Moleculin_Biotech_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Details for the poster presentation are as follows:","length":51,"tagName":"p"},{"type":"text","content":"Abstract: P002Session: Clinical Studies in AML and ALLTitle: Liposomal Annamycin in Combination with Cytarabine for Treatment of Acute Myeloid Leukemia (AML)Presenting Author: Cristina Papayannidis, MD, PhD, Adjunct professor, Department of Medical and Surgical Sciences, University of Bologna, Bologna Italy","length":326,"tagName":"p"},{"type":"text","content":"For more information about the ISALXIX International Symposium, visit the event website.","length":93,"tagName":"p"},{"type":"text","content":"About Moleculin Biotech, Inc.","length":34,"tagName":"p"},{"type":"text","content":"Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for ...